Isoantiserum-augmented development of lymphocyte-mediated cytotoxicity

J Exp Med. 1976 Nov 2;144(5):1284-93. doi: 10.1084/jem.144.5.1284.

Abstract

Passive administration of anti-P-814 isoantiserum (IS) with P-815 mastocytoma was shown to augment the development of T-lymphocyte-mediated cytotoxicity (LMC). The LMC activity augmented by IS was specific to immunizing tumor cells, but required the simultaneous administration of P-815 tumor cells and anti-P-815 serum, suggesting that the antigen-antibody complex is involved in the development of specific cytotoxic T cells. The serum component responsible for augmented development of LMC activity appeared to be IgM in that the augmenting activity fractionated in the void volume of a G-200 Sephadex column and appears very early after immunization. Our experimental results suggest the development of specific T-cell cytotoxicity can be directly regulated by specific IgM antibodies.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Neoplasm / administration & dosage
  • Antigen-Antibody Complex
  • Cytotoxicity Tests, Immunologic
  • Immunity, Cellular*
  • Immunization, Passive
  • Immunoglobulin M
  • Isoantibodies* / administration & dosage
  • Isoantibodies* / isolation & purification
  • Mice
  • Mice, Inbred Strains
  • Neoplasms, Experimental / immunology
  • T-Lymphocytes / immunology*

Substances

  • Antibodies, Neoplasm
  • Antigen-Antibody Complex
  • Immunoglobulin M
  • Isoantibodies